Circulating CD133+/ESA+ cells in colorectal cancer patients

Ju Yu Tseng, Chih Yung Yang, Shung Haur Yang, Jeng Kou Lin, Chi Hung Lin, Jeng Kai Jiang*

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Background: Tumor initiating cells are a small subset of cancer cells responsible for tumor growth and recurrence. The status of tumor initiating cells was measured using the surface markers CD133 (prominin-1) and ESA (epithelial-specific antigen). The aims of this study were to investigate the significance of CD133+/ESA+ cells in mesenteric venous blood (MVB) and tumor mass (TM) for overall survival (OS) and disease-free survival (DFS) in colorectal cancer (CRC) patients undergoing curative resection. Materials and methods: A total of 229 CRC patients undergoing curative resection were prospectively enrolled in the study. Using CD133 and ESA as surface markers, CD133+/ESA+ cells were enumerated from MVB and TM using flow cytometry. Results: We analyzed the presence of CD133+/ESA+ cells in TM from 158 patients and found no correlation to patient DFS, OS, or clinical stage. In 135 patients, an analysis of CD133+/ESA+ cells in MVB showed an inverse correlation with both DFS and OS (P=0.014 and P=0.008, respectively). It exhibited an increase-then-decrease pattern with the peak in stage II patients. A multivariate Cox analysis demonstrated that the status of CD133+/ESA+ cells in MVB, but not the TM, was a significant prognostic factor for DFS and OS (P=0.003 and P=0.011, respectively). Conclusions: The status of CD133+/ESA+ cells in MVB, but not in TM, could be a useful indicator for predicting tumor recurrence and a prognostic marker for CRC patients.

Original languageEnglish
JournalJournal of Surgical Research
Volume199
Issue number2
DOIs
StateAccepted/In press - 16 Apr 2015

Keywords

  • CD133
  • Epithelial-specific antigen
  • Prognosis

Fingerprint Dive into the research topics of 'Circulating CD133<sup>+</sup>/ESA<sup>+</sup> cells in colorectal cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Tseng, J. Y., Yang, C. Y., Yang, S. H., Lin, J. K., Lin, C. H., & Jiang, J. K. (Accepted/In press). Circulating CD133+/ESA+ cells in colorectal cancer patients. Journal of Surgical Research, 199(2). https://doi.org/10.1016/j.jss.2015.05.057